Clinical trials: Minimal Residual Disease
Ph+ ALL, Bone Marrow Transplant
A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
Hematopoietic stem cell transplantation (HSCT) is the effective and even the only cure treatment option for ph+ acute lymphocyte leukemia (ph+ALL).
- Conditions
- Ph+ ALL, Bone Marrow Transplant, Minimal Residual Disease
- Trial name
- NCT05603156
- Testing
- the usage of Olverembatinib combined with Inotuzumab Ozogamicin
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Gastrointestinal Stromal Tumors, Minimal Residual Disease
Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
So far, MRD assessment by liquid biopsy (ctDNA) has not been used to predict postoperative treatment efficacy and recurrence risk of GIST patients because of special disease characteristics and technological limitations.
- Trial name
- NCT05408897
- Testing
- liquid biopsy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking University People's Hospital
Non-small Cell Lung Cancer, Minimal Residual Disease
Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation
To study the efficacy of sintilimab combined with anlotinib for perioperative non-small cell lung cancer. To explore the clearance effect of sintilimab combined with anlotinib for postoperative adjuvant therapy based on…
- Conditions
- Non-small Cell Lung Cancer, Minimal Residual Disease, Immunotherapy, Anti-angiogenesis
- Trial name
- NCT05460195
- Testing
- sintilimab combined with anlotinib, sintilimab monotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shanghai Chest Hospital
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled…
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD19 Positive
- Trial name
- NCT02529813
- Testing
- Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia
Although studies are ongoing to evaluate the efficiency and safety of venetoclax-based therapy, alone or in combination with hypomethylation agent or low-dose cytarabine, in relapsed/refractory acute myeloid leukemia, data are…
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Minimal Residual Disease
- Trial name
- NCT05362942
- Testing
- Venetoclax, Decitabine, Azacytidine, Cytarabine
- Volunteers
- 52 people
- Sponsor
- Beijing 302 Hospital
Pediatric ALL, B Cell, Minimal Residual Disease
Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)
This is a single-arm, open-label, multi-center phase I study using blinatumomab for pediatric B-cell acute lymphoblastic leukemia patients with positive of minimal residual disease.
- Trial name
- NCT04604691
- Testing
- Blinatumomab for Injection
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
B-cell Adult Acute Lymphoblastic Leukemia, Stem Cell Leukemia
Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant
This is a single arm, open label, multi-centre phase II study using blinatumomab for treatment of detectable minimal residual disease (MRD) in the first year following allogeneic hematopoietic stem cell transplant (HSCT) for…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, Stem Cell Leukemia, Minimal Residual Disease
- Trial name
- OZM-097 (NCT04044560)
- Testing
- blinatumomab
- Where
- 3 sites in Canada
- Volunteers
- 8 people
- Sponsor
- University of British Columbia
Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
Various drugs have been added to different treatment regimens in order to improve the response rate in patients with Acute Lymphoblastic Leukemia, however, it has been shown that adding Bortezomib to the relapsing regimen…
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity, Minimal Residual Disease
- Trial name
- NCT05137860
- Testing
- Bortezomib
- Where
- Mexico
- Volunteers
- 56 people
- Sponsor
- Hospital General de Mexico
Minimal Residual Disease, Leukemia, Lymphoblastic, Acute
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
This study will test the ability of clofarabine + cytarabine to eliminate minimal residual disease (MRD) in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients whose bone marrows exhibit complete…
- Conditions
- Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute
- Trial name
- NCT01158885
- Testing
- Clofarabine, Cytarabine intravenous, Methotrexate
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
This randomized phase II trial studies how well treosulfan and fludarabine phosphate, with or without total body irradiation before donor stem cell transplant works in treating patients with myelodysplastic syndrome or acute…
- Conditions
- Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Minimal Residual Disease, Myelodysplastic Syndrome
- Trial name
- NCT01894477
- Testing
- Allogeneic Bone Marrow Transplantation, Fludarabine Phosphate, Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia, Minimal Residual Disease Negativity
Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia
This phase II trial studies how well autologous stem cell transplant works in treating patients with favorable or intermediate risk, minimal residual disease (MRD)-negative, acute myeloid leukemia.
- Trial name
- NCT03515707
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Etoposide
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Neoplastic Pathology, Minimal Residual Disease
Validation of a Method to Search Residual Disease in Auto-cryopreserved Ovarian Tissues
Cryopreservation of ovarian tissue is offered to young girls and women aged under 35 who have to undergo sterilizing gonadotoxic treatment, with the aim of preserving their fertility.
- Conditions
- Neoplastic Pathology, Minimal Residual Disease, Cryopreserved Ovarian Tissue
- Trial name
- VMRDO (NCT02900625)
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit
Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy
This phase II trial studies how well tislelizumab combined with DNA hypomethylation agent +/- CAG regimen (cytarabine, idarubicin / Aclarithromycin, rhG-CSF/ PEG-rhG-CSF) work in treating patients with high-risk acute myeloid…
- Conditions
- Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit, Acute Myeloid Leukemia With Positive Minimal Residual Disease
- Trial name
- NCT04541277
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Chinese PLA General Hospital
B Acute Lymphoblastic Leukemia, Minimal Residual Disease
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
This phase II trial studies how well pembrolizumab works in treating small amounts of cancer cells that remain after attempts to remove the cancer has been made in patients with acute lymphoblastic leukemia.
- Conditions
- B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Recurrent Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia
- Trial name
- NCT02767934
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
Patients with acute leukemia relapsing after allotransplant and who respond to anti-leukaemia interventions are at high-risk of a second relapse.
- Conditions
- Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation, Acute Leukemia, Minimal Residual Disease
- Trial name
- NCT03297528
- Testing
- donor lymphocyte infusion
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Acute Myeloid Leukemia, Minimal Residual Disease
MRD-directed Therapy for Low-risk and Intermediate-risk AML.
Acute myeloid leukemia(AML) patients with favorable and intermediate cytogenetics at diagnosis are generally excluded from first-line allo-SCT. However, these patients may eventually relapse in some cases.
- Trial name
- NCT02870777
- Testing
- MRD-directed therapy
- Where
- China
- Volunteers
- 743 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Minimal Residual Disease, Donor Lymphocyte Infusion
MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT
Allogeneic hematopoietic cell transplantation (Allo-HSCT) is an effective therapy for acute leukemia, but relapse remains an important problem.
- Conditions
- Minimal Residual Disease, Donor Lymphocyte Infusion, Hematopoietic Stem Cell Transplantation, Relapse
- Trial name
- NCT02673008
- Testing
- donor lymphocyte infusion
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Arthritis, Psoriatic, Ultrasonography
Ultrasound in Psoriatic Arthritis Treatment
BACKGROUND Psoriatic arthritis (PsA) is a systemic inflammatory disease with articular and extra-articular features. Establishing the prognosis of a patient with PsA is hence important to define the treatment strategy.
- Conditions
- Arthritis, Psoriatic, Ultrasonography, Minimal Disease, Residual
- Trial name
- UPSTREAM (NCT03330769)
- Testing
- New course of treatment
- Where
- 4 sites in Italy
- Volunteers
- 250 people
- Sponsor
- University of Cagliari
Colon Cancer, Minimal Residual Disease
Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery
The aim of this study is to compare the effects of three types of perioperative analgesia on the number of circulating cancer cells (representing minimal residual disease) following radical colon cancer surgery.
- Trial name
- NCT02314871
- Testing
- Epidural analgesia, Piritramide, Morphine
- Where
- 2 sites in Czechia
- Volunteers
- 60 people
- Sponsor
- The Institute of Molecular and Translational Medicine, Czech Republic
Acute Myeloid Leukemia (AML), Minimal Residual Disease
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
This is a phase I / II study. The purposes of this study are to: 1) find out what effects, good and/or bad, the combination of the experimental drug avelumab and the drug azacitidine has on people with AML and MRD, and 2) test if…
- Trial name
- NCT03699384
- Testing
- Azacitidine, Avelumab
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center